Wall Street analyst estimates for Can-Fite BioPharma Ltd. (CANF): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.05 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169500 | $844746 | $3.8M | $2.0M | $763000 | $853000 | $810000 | $743000 | $674000 | $408212 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $24190 |
| Gross Profit | $169500 | $844746 | $3.8M | $2.0M | $763000 | $853000 | $810000 | $743000 | $674000 | $384022 |
| Research & Development | $6.1M | $5.3M | $6.1M | $11.0M | $12.0M | $9.8M | $7.8M | $6.0M | $5.8M | $6.7M |
| Selling, General & Admin | $2.7M | $2.9M | $3.2M | $3.1M | $3.0M | $3.8M | $3.1M | $3.0M | $3.0M | $3.7M |
| Operating Expenses | $8.8M | $8.2M | $9.2M | $14.0M | $14.9M | $13.7M | $10.9M | $8.9M | $8.8M | $10.4M |
| Operating Income | -$8.6M | -$7.4M | -$5.4M | -$12.0M | -$14.1M | -$12.8M | -$10.1M | -$8.2M | -$8.1M | -$10.0M |
| EBITDA | -$8.7M | -$7.2M | -$6.1M | -$12.0M | -$14.1M | -$12.8M | -$10.1M | -$8.2M | -$8.1M | -$10.0M |
| Interest Expense | $27296 | $1.1M | $1.2M | $427000 | $363000 | $18000 | $77000 | $14000 | $14000 | $14111 |
| Pre-tax Income | -$7.0M | -$5.0M | -$6.6M | -$12.6M | -$14.4M | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.9M |
| Income Tax | $29116 | $29922 | $4000 | $427000 | 0 | -$20000 | $360000 | 0 | 0 | 0 |
| Net Income | -$6.9M | -$5.0M | -$6.6M | -$12.6M | -$14.4M | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.9M |
| EPS | $-0.60 | $-0.38 | $-0.34 | $-0.30 | $-0.08 | $-0.06 | $-0.03 | $-0.01 | $-0.01 | $-0.08 |
| EPS (Diluted) | $-0.60 | $-0.38 | $-0.34 | $-0.30 | $-0.08 | $-0.06 | $-0.03 | $-0.01 | $-0.01 | $-0.08 |
| Shares Outstanding (Diluted) | $13.8M | $16.3M | $19.5M | $43.0M | $179.2M | $276.5M | $407.9M | $639.2M | $1.09B | $123.6M |
Price
| Price | $2.24 |
| Market Cap | $3M |
| Exchange | AMEX |
| Country | IL |
Related companies: BDRX · CLDI · CMND · CNSP · GRI · JAGX · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CANF: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks